Global Persistent Corneal Epithelial Defects Treatment Market - Industry Trends and Forecast to 2027
- DAT3384329
- 344 Pages
- November 2019
- Pharmaceuticals
Market Segmentation:
Global persistent corneal epithelial defects treatment market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others), Type (Devices, Medication), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region (U.S., Canada and Mexico in North America, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Hungary, Lithuania, Austria, Ireland, Norway, Poland and Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America) Market Trends and Forecast to 2027.
Some of the major factors contributing to the growth of the market are:
• Increasing prevalence of persistent corneal epithelial defects and other related complications.
• Rising cases of eye surgeries and usage of contact lenses.
Market Players:
The key market players for global persistent corneal epithelial defects treatment market are listed below:
• Dompé Farmaceutici S.p.A
• Novartis AG
• Allergan
• Next Biosciences
• Katena Products. Inc.
• Johnson & Johnson Services, Inc.
• Hunt Valley PharmaLAB
• Laboratoires THEA S.A.S
• Skye Biologics Inc.
• I-MED Pharma inc.
• Almirall, S.A
• Ocular Science, Inc.
• Kala Pharmaceuticals
• Bausch Health
• Integra LifeSciences Corporation
• BioTissue (A Subsidiary of TissueTech, Inc.)
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET 42
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 PRODUCTS LIFELINE CURVE 52
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 55
2.11 SECONDARY SOURCES 56
2.12 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 MARKET OVERVIEW 60
4.1 DRIVERS 62
4.1.1 INCREASING PREVALENCE OF PERSISTENT CORNEAL EPITHELIAL DEFECTS AND OTHER RELATED COMPLICATIONS 62
4.1.2 RISING CASES OF EYE SURGERIES AND USAGE OF CONTACT LENSES 63
4.1.3 GROWING AGEING POPULATION AUGMENTING TOWARDS THE PCED CONDITION 64
4.1.4 INCREASE IN MECHANICAL TRAUMAS CASES 67
4.2 RESTRAINT 67
4.2.1 STRINGENT REGULATORY PROCEDURES 67
4.2.2 UNMET MEDICAL NEEDS FOR THE TREATMENT OF PCED 70
4.2.3 HIGH COST OF PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENTS 70
4.3 OPPORTUNITIES 71
4.3.1 DEVELOPMENT OF NOVEL THERAPEUTICS 71
4.3.2 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE 72
4.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 74
4.3.4 EMERGING MARKET ECONOMY CREATES SIGNIFICANT OPPORTUNITIES 74
4.4 CHALLENGES 76
4.4.1 DEPENDENCY ON THIRD PARTY SUPPLIERS 76
5 PREMIUM INSIGHTS 78
6 EPIDEMIOLOGY 80
7 GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,
BY CLINICAL CAUSES 81
7.1 OVERVIEW 82
7.2 INFLAMMATORY DISEASE 85
7.3 NEUROTROPHIC KERATITIS (NK) 85
7.4 EPITHELIAL/LIMBAL STEM CELL DEFICIENCY 86
7.5 OTHERS 87
8 GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,
BY TYPE 88
8.1 OVERVIEW 89
8.2 DEVICES 92
8.2.1 BANDAGE CONTACT LENS 93
8.2.2 AMNIOTIC MEMBRANE GRAFTS 93
8.2.3 PUNCTAL PLUGS 93
8.2.3.1 SILICONE PLUG 94
8.2.3.2 COLLAGEN PLUGS 94
8.2.4 CORNEAL TRANSPLANTS 94
8.2.4.1 KERATOPLASTY 94
8.2.4.2 KERATOPROSTHESIS 94
8.3 MEDICATION 95
8.3.1 DRUG TYPE 96
8.3.1.1 LUBRICANTS 96
8.3.1.2 PROPHYLACTIC TOPICAL ANTIBIOTICS 96
8.3.1.2.1 POLYMIXIN B–TRIMETHOPRIM + FLUOROQUINOLONE 97
8.3.1.2.2 FLUOROQUINOLONE 97
8.3.1.3 TOPICAL OPHTHALMIC STEROIDS 97
8.3.1.4 AUTOLOGOUS SERUM TEARS/AUTOLOGOUS SERUM EYE DROPS 97
8.3.1.5 TETRACYCLINES 97
8.3.1.6 HUMAN NERVE GROWTH FACTOR (OXERVATE) 97
8.3.1.7 WOUND HEALING AGENTS 97
8.3.1.8 OTHERS 97
8.3.2 ROUTE OF ADMINISTRATION 98
8.3.2.1 TOPICAL 98
8.3.2.2 ORAL 98
9 GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,
BY END USER 99
9.1 OVERVIEW 100
9.2 HOSPITALS 103
9.3 HOMECARE 103
9.4 SPECIALTY CLINICS 104
9.5 OTHERS 105
10 GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,
BY DISTRIBUTION CHANNEL 106
10.1 OVERVIEW 107
10.2 HOSPITAL PHARMACIES 110
10.3 RETAIL PHARMACIES 110
10.4 ONLINE PHARMACIES 111
11 GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET,
BY GEOGRAPHY 113
11.1 OVERVIEW 114
11.2 NORTH AMERICA 119
11.2.1 U.S. 126
11.2.2 CANADA 130
11.2.3 MEXICO 134
11.3 EUROPE 138
11.3.1 GERMANY 145
11.3.2 U.K. 149
11.3.3 FRANCE 152
11.3.4 ITALY 156
11.3.5 SPAIN 160
11.3.6 RUSSIA 164
11.3.7 NETHERLANDS 168
11.3.8 SWITZERLAND 172
11.3.9 BELGIUM 176
11.3.10 TURKEY 180
11.3.11 AUSTRIA 184
11.3.12 IRELAND 188
11.3.13 NORWAY 192
11.3.14 HUNGARY 196
11.3.15 POLAND 200
11.3.16 LITHUANIA 204
11.3.17 REST OF EUROPE 208
11.4 ASIA-PACIFIC 209
11.4.1 JAPAN 216
11.4.2 CHINA 220
11.4.3 INDIA 224
11.4.4 SOUTH KOREA 228
11.4.5 AUSTRALIA 232
11.4.6 SINGAPORE 236
11.4.7 THAILAND 240
11.4.8 MALAYSIA 244
11.4.9 INDONESIA 248
11.4.10 PHILIPPINES 252
11.4.11 VIETNAM 256
11.4.12 REST OF ASIA-PACIFIC 260
11.5 SOUTH AMERICA 261
11.5.1 BRAZIL 268
11.5.2 ARGENTINA 272
11.5.3 PERU 276
11.5.4 REST OF SOUTH AMERICA 280
11.6 MIDDLE EAST AND AFRICA 281
11.6.1 UAE 288
11.6.2 SAUDI ARABIA 292
11.6.3 SOUTH AFRICA 296
11.6.4 ISRAEL 300
11.6.5 KUWAIT 303
11.6.6 EGYPT 307
11.6.7 REST OF MIDDLE EAST AND AFRICA 311
12 GLOBAL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, COMPANY LANDSCAPE 312
12.1 COMPANY SHARE ANALYSIS: GLOBAL 312
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 313
12.3 COMPANY SHARE ANALYSIS: EUROPE 314
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 315
13 COMPANY PROFILE 316
13.1 JOHNSON & JOHNSON SERVICES, INC. 316
13.1.1 COMPANY SNAPSHOT 316
13.1.2 REVENUE ANALYSIS 316
13.1.3 COMPANY SHARE ANALYSIS 317
13.1.4 PRODUCT PORTFOLIO 317
13.1.5 RECENT DEVELOPMENTS 318
13.2 ALLERGAN 319
13.2.1 COMPANY SNAPSHOT 319
13.2.2 REVENUE ANALYSIS 319
13.2.3 COMPANY SHARE ANALYSIS 320
13.2.4 PRODUCT PORTFOLIO 320
13.2.5 RECENT DEVELOPMENT 320
13.3 BIO-TISSUE (A SUBSIDIARY OF TISSUETECH, INC.) 321
13.3.1 COMPANY SNAPSHOT 321
13.3.2 COMPANY SHARE ANALYSIS 321
13.3.3 PRODUCT PORTFOLIO 321
13.3.4 RECENT DEVELOPMENTS 322
13.4 LABORATOIRES THÉA S.A.S 323
13.4.1 COMPANY SNAPSHOT 323
13.4.2 COMPANY SHARE ANALYSIS 323
13.4.3 PRODUCT PORTFOLIO 323
13.4.4 RECENT DEVELOPMENT 323
13.5 NOVARTIS AG 324
13.5.1 COMPANY SNAPSHOT 324
13.5.2 REVENUE ANALYSIS 324
13.5.3 PRODUCT PORTFOLIO 325
13.5.4 RECENT DEVELOPMENT 325
13.6 BAUSCH HEALTH 326
13.6.1 COMPANY SNAPSHOT 326
13.6.2 REVENUE ANALYSIS 326
13.6.3 PRODUCT PORTFOLIO 327
13.6.4 RECENT DEVELOPMENT 327
13.7 INTEGRA LIFESCIENCES CORPORATION 328
13.7.1 COMPANY SNAPSHOT 328
13.7.2 REVENUE ANALYSIS 328
13.7.3 PRODUCT PORTFOLIO 329
13.7.4 RECENT DEVELOPMENT 329
13.8 ALMIRALL, S.A 330
13.8.1 COMPANY SNAPSHOT 330
13.8.2 REVENUE ANALYSIS 330
13.8.3 PRODUCT PORTFOLIO 331
13.8.4 RECENT DEVELOPMENT 331
13.9 DOMPÉ FARMACEUTICI S.P.A. 332
13.9.1 COMPANY SNAPSHOT 332
13.9.2 PRODUCT PORTFOLIO 332
13.9.3 RECENT DEVELOPMENTS 332
13.10 HUNT VALLEY PHARMALAB 333
13.10.1 COMPANY SNAPSHOT 333
13.10.2 PRODUCT PORTFOLIO 333
13.10.3 RECENT DEVELOPMENT 333
13.11 I-MED PHARMA INC. 334
13.11.1 COMPANY SNAPSHOT 334
13.11.2 PRODUCT PORTFOLIO 334
13.11.3 RECENT DEVELOPMENT 334
13.12 KALA PHARMACEUTICALS 335
13.12.1 COMPANY SNAPSHOT 335
13.12.2 PRODUCT PORTFOLIO 335
13.12.3 RECENT DEVELOPMENTS 335
13.13 KATENA PRODUCTS. INC. 336
13.13.1 COMPANY SNAPSHOT 336
13.13.2 PRODUCT PORTFOLIO 336
13.13.3 RECENT DEVELOPMENTS 337
13.14 NEXT BIOSCIENCES 338
13.14.1 COMPANY SNAPSHOT 338
13.14.2 PRODUCT PORTFOLIO 338
13.14.3 RECENT DEVELOPMENT 338
13.15 OCULAR SCIENCE, INC. 339
13.15.1 COMPANY SNAPSHOT 339
13.15.2 PRODUCT PORTFOLIO 339
13.15.3 RECENT DEVELOPMENT 339
13.16 SKYE BIOLOGICS INC. 340
13.16.1 COMPANY SNAPSHOT 340
13.16.2 PRODUCT PORTFOLIO 340
13.16.3 RECENT DEVELOPMENT 340
14 QUESTIONNAIRE 341
15 RELATED REPORTS 344
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
